PND7 Total Migraine freedom for breath powered intranasal delivery of 22 mg Sumatriptan Powder (Avp-825) Versus 100 mg oral sumatriptan from the compass study of acute treatment of Migraine  by Halker, R. et al.
A278  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  
the overall diagnostic accuracy from these tests. METHODS: We conducted a 
systematic review in five different electronic databases: Pubmed, Embase, The 
Cochrane Library, Database of Abstracts of Reviews of Effect (DARE) and Lilacs. 
We included both case control and consecutive enrollment studies that evalu-
ated the performance of the immunoassays in patients with suspected NMO in 
comparison with the 2006 Wingerchuk diagnostic criteria. Articles were assessed 
by two different reviewers, who also extracted data. RESULTS: 29 studies for three 
different immunoassays were included in the meta-analysis. To obtain a sum-
mary estimate for the sensitivity and specificity with 95% confidence interval 
a bivariate random effect model was used. The approximated sensitivity for the 
cell based assay, the tissue based assay and the ELISA test were 0.77(CI 95% 0.68-
0.84), 0.63(CI 95% 0.54-0.72) and 0.62(CI 95% 0.52-0.72), respectively. The mean 
specificity of the cell based assay was 0.99 (CI 95% 0.98-0.99), tissue based assay 
0.99 (CI 95% 0.97-0.99) and Elisa test 0.97(CI 95% 0.95-0.99). CONCLUSIONS: AQP4 
detection in serum with immunoassay is a great tool for the diagnosis of patients 
with NMO, due to the high specificity, allowing the clinician to differentiate this 
disease from other neurological conditions that resemble NMO. Due to differences 
in test effectiveness, cost-minimization studies would not be appropriate. Since 
the cost of immunoassays differs, these results will be useful in cost-effectiveness 
models.
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OBJECTIVES: Lipodystrophy syndromes (LD-S) are serious medical conditions char-
acterized by selective absence of the body’s adipose tissue, typically associated with 
insulin resistance, diabetes, dyslipidemia and other systemic diseases. Prevalence 
and natural history data on LD-S are sparse, derived primarily from anecdotal phy-
sician experience and case reports. This study explored the usefulness of EMRs for 
evaluating prevalence, natural history and disease burden of LD-S. METHODS: A 
unique retrospective cohort study of real-world EMR data along with expert review 
of text strings available in physician notes was conducted to classify and compare 
patients with an ICD-9-CM indication of LD-S (ICD-9-CM code 272.6), by type (con-
genital or acquired, generalized or partial, localized, or unable to classify). Data were 
captured from a large national network of US providers from 2000-2014, and limited 
to patients with no evidence of HIV. RESULTS: 1,637 patients with an ICD-9-CM 
diagnosis indicating LD-S and no evidence of HIV were identified. Upon detailed 
review of physician notes, 49 patients (3%) were classified as congenital general-
ized or partial LD, 227 (14%) as localized LD, and the remainder (83%) were unable 
to be classified due to non-specific physician notes. Among these subgroups, 71%, 
24% and 23% had high triglycerides (> 200 mg/dL); 69%, 30%, and 26% had Type 2 
diabetes; and 8%, 30%, and 12% had Type 1 diabetes, respectively. In the localized and 
unclassified groups, treatment by dermatologists and plastic surgeons was more 
common (18-30% versus 0%), and patients were more likely obese (18-21% versus 
16%). CONCLUSIONS: Over 80% of patients with an ICD-9-CM diagnosis indicating 
LD-S could not be classified due to non-specificity of coding. Given the current lack 
of standardization of the diagnostic code, it will be difficult to understand the true 
prevalence and natural history of LD-S utilizing EMR without an effort to standardize 
coding and documentation of LD-S.
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OBJECTIVES: Migraine-associated symptoms—nausea, photophobia and/or pho-
nophobia—can contribute to disability and direct healthcare costs. The com-
posite efficacy endpoint, total migraine freedom (TMF), is more rigorous than 
other pain endpoints and assesses pain freedom and absence of migraine-asso-
ciated symptoms, providing a more comprehensive understanding of treatment 
impact than evaluation of items individually. TMF was assessed for AVP-825, 
an investigational Breath Powered intranasal delivery system containing 22mg 
sumatriptan powder, vs 100mg oral sumatriptan (oral-SUM) in the COMPASS study 
(NCT01667679). METHODS: Multicenter, double-dummy, crossover, multi-attack 
study with two 12-week double-blind periods. Patients (2–8 attacks/month) were 
randomized to AVP-825 plus oral placebo or an identical placebo delivery system 
plus 100mg oral-SUM (period-1); treatment switched for period-2. Patients treated ≤ 5 
qualifying migraines/period (< 1 hour from onset, even if mild). Percentage of attacks 
with TMF (pain freedom and absence of migraine-associated symptoms, including 
vomiting) at timepoints from 10 minutes–2 hours post-dose was calculated post 
hoc and analyzed by chi-square test. RESULTS: 185 patients treated migraines in 
both periods, yielding 1531 migraines assessed (765 AVP-825, 766 oral-SUM). The 
percentage of attacks with TMF was significantly greater with AVP-825 vs oral-
SUM at all timepoints from 15–90 minutes: 15 minutes (7.2% vs 3.7%; P< .01), 30 
minutes (18.0% vs 10.8%; P< .001), 45 minutes (30.7% vs 21.4%; P< .001), 60 minutes 
(40.9% vs 33.3%; P< .01), 90 minutes (52.7% vs 45.6%; P< .01). At 2 hours, TMF rates did 
not differ significantly between treatments (60.6% for AVP-825 vs 56.7% oral-SUM; 
P= .11). CONCLUSIONS: AVP-825 (22mg sumatriptan) treatment of acute migraine 
results in higher rates of TMF at earlier timepoints than the most efficacious dose 
(100mg) of oral-SUM, despite delivering much less drug. These results demonstrate 
the superiority of AVP-825 using the most rigorous efficacy endpoint in migraine 
and are consistent with the other outcomes of COMPASS, indicating AVP-825 has 
superior early efficacy compared to oral-SUM.
est VPA concentrations were also higher when concomitant administrated of 
Biapenem compared to Meropenem . The rate of seizures in Biapenem group 
and Meropenem group were 29.73% and 35.42% respectively(P= 0.749). Most 
physicians discontinued the carbapenems, increased the VPA dose or added 
other antiepileptic drugs. CONCLUSIONS: The extent of decrease in VPA serum 
concentrations was greater in meropenem-treated patients than in biapenem-
treated cases. But Biapenem also decreased the VPA blood level as 70% and 
increased the risk of seizures , concomitant using of these medications should be 
avoided.
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OBJECTIVES: Chronic cluster headache (CCH) is a type of headache where attacks 
occur for more than a year without remission. The objective of this study was to 
identify evidence (a) on the disease and comorbidities burden (epidemiological, 
economic, humanistic) and (b) on the economic burden, complications and effi-
cacy of treatments recommended by the European Federation of the Neurological 
Societies (EFNS) guidelines. METHODS: Medline, Embase, Cochrane Library and 
NHS EED were searched using a predefined search strategy and selection criteria to 
retrieve publications on CCH in English language from 2000 onwards. RESULTS: In 
total, 10 studies were retrieved reporting data on disease burden and comorbidities 
of CCH. Of them, four reported humanistic burden, three reported comorbidities, 
two epidemiological outcomes and one study published economic data. Seven 
studies reported male-to-female ratio ranging from 3.0:1 to 4.65:1. Patient char-
acteristics were variable and inconsistent across studies. Four studies reported 
data on humanistic burden identified as depression, long-term disability, work 
loss and decreased ability to participate in social, family and housework activities. 
Economic burden was reported as number of visits to neurologists and neurosur-
geons and length of hospital stay. Five studies reported data on efficacy and safety 
of EFNS recommended CCH treatments, of which 3 were randomized controlled 
trials. Three studies reported overall response rates (ranging from 16-36%); two 
reported need for rescue medications (28-39%), pain-free at 30 minutes (37-47%) 
and headache relief at 30 minutes (47-52%). Two studies reported safety outcomes: 
zero adverse events and zero serious adverse events. No data on the economic 
burden of EFNS recommended treatments were identified. CONCLUSIONS: This 
review shows a large evidence gap regarding the disease burden, efficacy and 
safety of recommended treatments in CCH patients. The considerable impact of 
the economic, humanistic burden and comorbidities of CCH is indisputable for 
both the patient and the society.
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OBJECTIVES: Despite well-known benefits of pharmacotherapy to treat Parkinson 
disease (PD), conventional interventions may increase an individual’s risk of 
severe and sometimes life-threatening adverse outcomes. Our primary objective 
was to examine the risk of cardiovascular events, including acute myocardial 
infarction, heart failure, hypotension, and valvulopathy, among hospitalized 
individuals who received pharmacotherapy for PD. We hypothesized that indi-
viduals treated with non-ergot dopamine agonists (DAs) would be more likely to 
be diagnosed with cardiovascular events. We also examined the risk of cerebro-
vascular events (cerebrovascular accident and ischemic stroke) and the risk of 
adverse events among non-ergot DA only users. METHODS: Retrospective study 
of 14,122 inpatients identified from the Cerner Health Facts® database between 
January 1, 2000 and December 31, 2012 who received pharmacological treat-
ment for PD. Controls were matched to cases on age, race, and sex. Multivariable 
logistic regressions were used to estimate associations between non-ergot DA 
exposure and the risk of adverse events. Risk estimates were calculated as odd 
ratios (OR) with 95% confidence intervals (CI). RESULTS: Inpatients were primarily 
Caucasian (91.2%), men (54.0%), and 80 years of age or older (47.4%) at admission. 
The majority of patients were levodopa users (87.2%) and antiparkinson mono-
therapy was common (71.7%). Relative to levodopa monotherapy, an increased risk 
of heart failure was observed with non-ergot DA (OR 1.22, CI 1.02-1.50, p = 0.04) 
and pramipexole monotherapy (OR 1.29, CI 1.00-1.66, p = 0.05). No risk of other 
cardiovascular events or cerebrovascular events was identified. CONCLUSIONS: 
Treating PD provides substantial benefits to function, mobility, and survival. It is 
important to treat PD; therefore, knowledge of cardiovascular and cerebrovascu-
lar risks associated with pharmacotherapies is essential to informing treatment 
decisions.
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OBJECTIVES: Antibodies against water channel protein aquaporin 4 (AQP4) in 
astrocytes play a role in the etiology and physiopathology of neuromyelitis optica 
(NMO); detection of this immunoglobulin in serum is highly suggestive of this 
diagnosis. There are several immunoassays to detect the antibody with differ-
ent sensitivities and specificities. We conducted a meta-analysis to determine 
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well-defined and diverse PBA patient population, showing statistically significant 
improvements in a range of validated clinical and HRQoL outcomes relevant for 
the treatment of PBA. CONCLUSIONS: The evidence base for off-label agents used 
for treatment of PBA is limited, relying on small often uncontrolled studies show-
ing ill-defined treatment effects and little or no safety tracking. DM/Q is the only 
treatment for PBA that has demonstrated efficacy in well-conducted clinical trials 
in patients with varied neurological disorders.
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OBJECTIVES: Teriflunomide is a once-daily oral immunomodulator approved for 
relapsing-remitting MS. Here we report the key efficacy, safety, and post hoc analy-
ses from the randomized, placebo-controlled phase 3 trials TEMSO (NCT00134563) 
and TOWER (NCT00751881). METHODS: In TEMSO/TOWER, a total of 1088/1169 
patients with relapsing MS were randomized (1:1:1) to once-daily teriflunomide 14 
mg, teriflunomide 7 mg, or placebo. Treatment duration was 108 weeks (TEMSO) or 
variable, based on time of enrollment (TOWER; 48–152 weeks, ending 48 weeks after 
last patient randomized). Primary and key secondary endpoints were annualized 
relapse rate (ARR) and disability progression confirmed for 12 weeks. Additional 
endpoints included safety and tolerability. Post hoc analyses examined the effect 
of teriflunomide on 5 severe relapse outcomes: (A) relapses with sequelae defined 
by increase in Expanded Disability Status Scale score/Functional Score 30 days 
postrelapse; (B) relapses with investigator-defined sequelae; (C) severe relapses by 
Panitch definition; (D) relapses leading to hospitalization; and (E) relapses requir-
ing treatment with intravenous corticosteroids. RESULTS: In TEMSO/TOWER, 
teriflunomide 14 mg significantly reduced both ARR and disability progression vs 
placebo. Teriflunomide 7 mg significantly reduced ARR but not disability progres-
sion. Teriflunomide 14 mg significantly reduced annualized rates of severe relapse 
outcomes compared with placebo in TEMSO/TOWER by: (A) 36.2% (P= 0.0011)/36.6% 
(P= 0.0021); (B) 52.6% (P< 0.0001)/53.5% (P= 0.0004); (C) 38.5% (P= 0.0286)/52.5% 
(P= 0.0015); (D) 59.3% (P< 0.0001)/33.6% (P= 0.0155); and (E) 33.7% (P= 0.0003)/35.7% 
(P= 0.0002). Teriflunomide 7 mg also reduced annualized rates of severe relapses, 
although not significantly in all definitions. Both teriflunomide doses showed simi-
lar safety profiles across the 2 studies. CONCLUSIONS: Teriflunomide 14 mg has 
shown consistent and significant positive effects on ARR and disability progression 
in 2 phase 3 studies. Teriflunomide also reduces severe relapses as measured by 
various relapse definitions, which may reduce relapse-related healthcare costs and 
improve patients’ quality of life.
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OBJECTIVES: Multiple sclerosis (MS) disease progression is measured by the 
Expanded Disability Status Scale (EDSS). UK MS clinical guidelines1recommend that 
patients discontinue treatment with disease modifying therapies (DMTs) on reach-
ing EDSS ≥ 7.0, or experiencing non-relapsing secondary progressive MS (SPMS). This 
study derived the time for patients to reach EDSS ≥ 7.0 or SPMS from EDSS 4.0 or 
5.0, for patients treated with delayed-release dimethyl fumarate 240mg (DMF; also 
known as gastro-resistant DMF), or no DMT treatment. METHODS: The time taken 
to reach relapsing-remitting MS (RRMS) EDSS ≥ 7.0, or SPMS (any EDSS state) from 
EDSS 4.0 or 5.0 was estimated from transition probability matrices using algebraic 
techniques from Mandel 20072: the time to EDSS ≥ 7.0 or SPMS was derived for each 
matrix (DMF, untreated) by using matrix multiplication to estimate the proportion of 
patients who had reached these states over time. The transition matrix for untreated 
patients was derived using placebo arm data from clinical trials3,4(for RRMS popula-
tion) and London Ontario dataset (for transitions from RRMS to SPMS). The transition 
matrix for DMF was estimated by applying treatment effect on disability progression 
(sourced from a mixed treatment comparison), to the probability of progressing in 
the untreated matrix. Probabilistic sensitivity analysis was conducted to estimate 
95% confidence intervals (CIs). RESULTS: The time for progression from EDSS 4.0 
to ≥ 7.0 or SPMS was 8.53 years (95% CI: 7.05-10.25) for patients treated with DMF 
and 5.90 years (95% CI: 5.59-6.24) for untreated patients. The time from EDSS 5.0 to 
≥ 7.0 or SPMS was 5.28 years (95% CI: 4.32-6.37) for patients treated with DMF and 
3.64 years (95% CI: 3.34-3.96) for untreated patients. CONCLUSIONS: Our analysis 
showed that DMF therapy was associated with a longer time interval between EDSS 
4.0 or 5.0 and progression to EDSS ≥ 7.0 or SPMS relative to no DMT treatment.
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OBJECTIVES: Teriflunomide and dimethyl fumarate (DMF), oral therapies for 
relapsing-remitting MS, have demonstrated efficacy in clinical trials on magnetic 
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OBJECTIVES: IPX066, an extended-release capsule formulation of carbidopa-levo-
dopa (CD-LD), is designed to produce a rapid increase in plasma levodopa concen-
trations similar to immediate-release CD-LD (IR), but with sustained plasma levels 
allowing dosing every 6 hours. This post hoc analysis investigated whether baseline 
Parkinson’s disease (PD) severity influenced the patient reported efficacy of IPX066 
vs. IR in advanced PD patients. METHODS: IPX066 was evaluated in a randomized, 
double-blind, Phase 3 study vs. IR CD-LD for 13 weeks (N= 393). Patients were split 
into subgroups of higher and lower disease severity based on median baseline “off” 
time (5.67 hr) and Unified Parkinson’s Disease Rating Scale (UPDRS) Parts II+III 
(score: 32). Patient Global Impression (PGI), and the change from baseline in “off” 
time and “on” time with troublesome dyskinesia by PD diary were analyzed for 
each subgroup. RESULTS: IPX066 significantly improved PGI (P< .0001) and “off” time 
(P< .0001) compared with IR CD-LD in the overall randomized population. IPX066 
significantly improved PGI scores compared with IR CD-LD in both higher severity 
subgroups (P< .001) and lower severity subgroups (P< .02). Numerical improvements 
from baseline in “off” time were seen with IPX066 vs. IR CD-LD in each disease sever-
ity subgroup. The improvements in “off” time were significantly greater for IPX066 
vs. IR CD-LD in the higher severity “off” (P< .0001) and in both the higher (P= .02) and 
lower severity (P= .0001) UPDRS subgroups. The improvement by IPX066 compared 
to IR CD-LD in the lower severity “off” subgroup did not reach significance (P= .11), 
possibly due to a floor effect. IPX066 did not significantly worsen “on” time with trou-
blesome dyskinesia compared to IR CD-LD in any subgroup (P> .14). CONCLUSIONS: 
Advanced PD patients reported higher global impression of change and greater 
improvements in “off” time without worsening troublesome dyskinesia after treat-
ment with IPX066 compared with IR CD-LD, regardless of disease severity subgroup.
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OBJECTIVES: We performed a systematic review of randomized controlled tri-
als (RCTs) to estimate the efficacy of melatonin versus placebo or other hypnotic 
agents on the improvement of sleep quality and quantity in patients with primary 
insomnia. METHODS: We searched the published literatures in eight electronic 
databases, including Ovid-Medline, EMBASE, the Cochrane Library, and five Korean 
databases through October 2014. We included articles comparing efficacy for sleep 
between melatonin and placebo or other hypnotics among primary insomnia 
patients. The quality of studies was evaluated by using the Cochrane’s risk of bias. 
The mean difference (MD) or standardized mean difference (SMD) was calculated 
using the random-effects method for each study outcome. To assess heterogene-
ity of inter-trial, we used the I2-statistic. Subgroup-analyses were performed by 
assessment tools, study designs, ages and dosage of melatonin. Funnel plots were 
used to assess publication bias. RESULTS: Eighteen RCTs were identified and the 
comparison groups of all included trials were placebo. Compared with placebo, 
melatonin significantly reduced sleep onset latency (MD: -6.58 min [95% confidential 
interval (CI): -9.75 to -3.41], p < 0.0001), and increased total sleep time (MD: 20.56 
min [95% CI: 4.70 to 36.41], p = 0.01) and sleep efficiency (MD: 3.47% [95% CI: 0.37 to 
6.58], p = 0.03). Sleep quality was also improved (SMD: 0.22 [95% CI: 0.03 to 0.40], p = 
0.02) in melatonin group but this result was concluded based on a small number of 
studies. In subgroup-analyses for each outcome, there was no clinically remarkable 
finding. We did not find any evidence of statistical heterogeneity and publication 
bias. CONCLUSIONS: Melatonin showed to be effective for sleep in comparison 
with placebo, thus can be an effective option for the treatment of insomnia. Further 
studies are needed to conclude safety profiles, economic usefulness and tolerance 
of melatonin.
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OBJECTIVES: PBA is a neurologic disorder characterized by involuntary, uncontrol-
lable laughing and/or crying episodes that are often incongruent with the patient’s 
internal emotional state; PBA has also been called pathological laughing/crying, 
emotionalism, etc. Until FDA approval of dextromethorphan/quinidine (DM/Q) in 
2010, multiple agents including antidepressants, antipsychotics, dopamine ago-
nists and sedatives were used off-label for the management of PBA symptoms. 
We conducted a systematic review of therapies (licensed and unlicensed) for PBA 
symptoms to evaluate their relative clinical effectiveness METHODS: Databases: 
Medline, Medline in process, Embase and the Cochrane central register of con-
trolled trials; conference abstracts were searched in Embase. Study type: RCTs and 
non-RCTs in adult patients with PBA/PBA-like symptoms (pathological laughing/
crying, emotionalism, etc). Interventions: DM/Q, antidepressants, antipsychotics, 
dextromethorphan and quinidine alone. Outcome measures: change from baseline 
in various measures of PBA/emotionalism symptoms or symptom burden (NPI, 
SF-36, PRS scores and the caregiver strain index (CSI)). RESULTS: Nine RCTs and 
three observational studies were included. Among off-label drugs, six RCTs of 3 
SSRIs and 2 TCAs showed improvements in disparate PBA symptom measures, only 
1 used a validated symptom measure. These studies were small (N= 6-28) using 
mostly stroke patients. They were heterogeneous on how they defined/diagnosed 
PBA and varied in duration (1.4-24 weeks). As such, no formal evidence synthesis 
was possible. Three RCTs and one open label trial investigating DM/Q included a 
